Affinium closes $15 million financing round

Affinium Pharmaceuticals announced today the closing of its $15 million financing.  Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.

"We're very pleased with the confidence and support shown by our investors in closing this financing round and delighted to have the OETF join us," commented Owen Roberts, Chief Financial Officer of Affinium Pharmaceuticals.

"This financing will fully fund Affinium's next two key development goals, the completion of a phase 2 trial for our oral tablet and phase 1 trials of our new IV formulations" said Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals.

Affinium will initiate shortly a phase 2 clinical study of oral AFN-1252 in acute bacterial skin and skin structure infections.